Literature DB >> 9058810

Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis.

M Vergelli1, B Hemmer, P A Muraro, L Tranquill, W E Biddison, A Sarin, H F McFarland, R Martin.   

Abstract

It is well established that target cell lysis by MHC class I-restricted CD8+ T cells is an important defense mechanism during infections with intracellular pathogens or against tumor targets. On the other hand, little is known about the physiologic role and the mechanisms of cytotoxicity of CD4+ MHC class II-restricted T cells. We have recently demonstrated that human autoreactive CD4+ T cells specific for one candidate autoantigen of multiple sclerosis, myelin basic protein, can mediate cytotoxicity. In the present report, we analyze the cytolytic mechanisms employed by these cells. We show that individual T cell clones, regardless of their cytokine phenotype, can be noncytotoxic or lyse target cells via either perforin- or Fas/Fas ligand-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058810

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.

Authors:  E Chang; L Galle; D Maggs; D M Estes; W J Mitchell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  A comparative study of the expression of cytotoxic proteins in allergic contact dermatitis and psoriasis: spongiotic skin lesions in allergic contact dermatitis are highly infiltrated by T cells expressing perforin and granzyme B.

Authors:  N Yawalkar; R E Hunger; C Buri; S Schmid; F Egli; C U Brand; C Mueller; W J Pichler; L R Braathen
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 3.  The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage.

Authors:  Wolfgang Brück
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

4.  In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model.

Authors:  T Cao; P Meuleman; I Desombere; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones.

Authors:  S J Gagnon; F A Ennis; A L Rothman
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Effector Th-1 cells with cytotoxic function in the intestinal lamina propria of patients with Crohn's disease.

Authors:  P Mariani; A Bachetoni; M D'Alessandro; D Lomanto; P Mazzocchi; V Speranza
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

7.  An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells.

Authors:  G Eberl; S Jiang; Z Yu; P Schneider; G Corradin; J P Mach
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.

Authors:  Jacqueline A Quandt; Jaebong Huh; Mirza Baig; Karen Yao; Naoko Ito; Mark Bryant; Kazuyuki Kawamura; Clemencia Pinilla; Henry F McFarland; Roland Martin; Kouichi Ito
Journal:  J Immunol       Date:  2012-08-10       Impact factor: 5.422

9.  T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions.

Authors:  Marisa Benagiano; Annalisa Azzurri; Alessandra Ciervo; Amedeo Amedei; Carlo Tamburini; Mauro Ferrari; John L Telford; Cosima T Baldari; Sergio Romagnani; Antonio Cassone; Mario M D'Elios; Gianfranco Del Prete
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-09       Impact factor: 11.205

Review 10.  Programmed cell death: the influence of CD40, CD95 (Fas or Apo-I) and their ligands.

Authors:  N Laytragoon-Lewin
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.